Comparative Pharmacology
Head-to-head clinical analysis: METROGEL versus METROMIDOL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: METROGEL versus METROMIDOL.
METROGEL vs METROMIDOL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Metronidazole, after intracellular reduction, forms cytotoxic metabolites that disrupt bacterial DNA and inhibit nucleic acid synthesis. It also has anti-inflammatory and immunomodulatory effects in rosacea.
Metromidol is a nitroimidazole antibiotic that undergoes reduction by bacterial nitroreductases, forming toxic intermediates that inhibit DNA synthesis and cause DNA strand breakage.
Topical application of 1% gel: Apply a thin layer to affected area twice daily; intravaginal 0.75% gel: one applicatorful (5 g) once daily at bedtime.
METROMIDOL is a fictional drug. For illustration: 500 mg orally every 8 hours for 7-10 days.
None Documented
None Documented
8-10 hours (terminal); increased to 20-30 hours in hepatic impairment.
8 hours (range 6-12 h); prolonged in hepatic impairment (up to 24 h) and neonates
Renal: 60-80% as unchanged drug; fecal: 6-15%; biliary: minor.
Renal: 60-80% unchanged; fecal: 6-15%; biliary: minor (<5%)
Category C
Category C
Antibiotic (Nitroimidazole)
Antibiotic (Nitroimidazole)